2021 MO – Experimental Tubulointerstitial Disease

D ROJAS-CANALES 1,3, E TUCKER 3, K MCNICHOLAS 3, A MEHDORN 2, J GLEADLE 1,3 1Department of Renal Medicine, Flinders Medical Centre, Southern Adelaide Local Health Network, Bedford Park, Australia, 2Flinders Centre for Innovation in Cancer, Department of Gastroenterology and...
HARLEY G1, KATERELOS M1, GLEICH K1, MOUNT P1,2, POWER D1,2 1Austin Health, Melbourne, Australia, 2University of Melbourne, Melbourne, Australia Aim: To determine if modification of glycolysis has a critical role in metformin’s protective effects against renal fibrosis. Background: Metformin has...
M Khan1,2,3,4,P  Nag3,5, K Giuliani2,3,5,X  Wang3,5, A Grivei3,5, W Hoy1,7, H Healy1,2,3,5, V Dewan1,7, G Gobe1,2,6, A Kassianos2,3,5  1NHMRC CKD CRE (CKD.QLD), University of Queensland , Brisbane,, Australia, 2Faculty of Medicine, University of Queensland, Brisbane,, Australia, 3Conjoint Internal Medicine Laboratory, Chemical Pathology, Pathology...
P MEHTA 1,  T SLATTER 1,  R WALKER 1 1University of Otago, Dunedin, New Zealand Aim: To explore pathways through which amiloride reduces lithium-induced interstitial fibrosis. Background: Lithium therapy is associated with the development of nephrogenic diabetes insipidus (NDI), interstitial fibrosis and...
Recent Comments
    Categories